On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental application for atezolizumab, marketed as Tecentriq. This approval, categorized under efficacy, signifies an update to the drug's label based on new clinical data.
Background
Atezolizumab (Tecentriq) is a therapeutic agent developed by Genentech Inc. The FDA's review of this supplemental application focused on its efficacy, indicating new evidence supporting its therapeutic benefits. Atezolizumab is also known by its full name, atezolizumab and hyaluronidase-tqjs, and the brand name Tecentriq Hybreza.
What this means
The FDA's approval of a supplemental Biologics License Application (BLA) for atezolizumab (Tecentriq) confirms that new efficacy data has been reviewed and deemed sufficient to warrant an update to the drug's official prescribing information. While the specific details of the expanded indication, patient population, or updated dosing associated with this particular supplemental approval are not provided in the source data, such approvals generally allow for broader or refined use of the medication. This process ensures that the drug's label accurately reflects the latest scientific understanding of its benefits and risks, providing clinicians with updated guidance for patient care. For patients, this could mean new treatment options or improved understanding of existing ones.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for Biologics License Application (BLA) 761034 S-19 for Tecentriq (atezolizumab) was granted on March 18, 2019, and is publicly accessible via accessdata.fda.gov.